Patents
Literature
3 results about "Carfilzomib" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Carfilzomib (marketed under the trade name Kyprolis, developed by Onyx Pharmaceuticals) is an anti-cancer drug acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin.
Compositions comprising Anti-CD38 antibodies and carfilzomib
Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.
Owner:SANOFI AVENTIS US LLC +1
Methods of treating multiple myeloma
ActiveUS12636340B2Organic active ingredientsTetrapeptide ingredientsDexamethasoneAntiendomysial antibodies
Provided herein are methods of treating a subject suffering from multiple myeloma by administering a triplet therapy of carfilzomib, dexamethasone, and an antibody that specifically recognizes CD38.
Owner:ONYX PHARMACEUTICALS INC +1